DUBLIN, Oct. 15, 2021 /PRNewswire/ -- The "Global Agricultural Biotechnology Market 2020-2030 by Product, Technology, Application, and Region: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Global agricultural biotechnology market will reach $115.0 billion by 2030, growing by 9.8% annually over 2020-2030 owing to the rising population, the burgeoning demand for food, and the rising adoption of enhanced technologies for crop cultivation.

This report is based on a comprehensive research of the entire global agricultural biotechnology market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate and forecast from 2020 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).

In-depth qualitative analyses include identification and investigation of the following aspects:

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global agricultural biotechnology market in every aspect of the classification from perspectives of Product, Technology, Application, and Region.

Key Topics Covered:

1 Introduction

2 Market Overview and Dynamics2.1 Market Size and Forecast2.1.1 Impact of COVID-19 on World Economy2.1.2 Impact of COVID-19 on the Market2.2 Major Growth Drivers2.3 Market Restraints and Challenges2.4 Emerging Opportunities and Market Trends2.5 Porter's Five Forces Analysis

3 Segmentation of Global Market by Product3.1 Market Overview by Product3.2 Biotech Seeds3.2.1 Biotech Seeds by Breeding Type3.2.2 Biotech Seeds by Trait Type3.2.3 Biotech Seeds by Crop Type3.3 Biologicals3.3.1 Biopesticides3.3.2 Biostimulants3.3.3 Biofertilizers3.3.4 Genetic Biologicals3.4 Biotechnology Tools3.4.1 DNA Sequencing3.4.2 Biochips3.4.3 Gene Editing3.4.4 Synthetic Biology3.4.5 RNA Interference3.5 Synthetic Biology-enabled Products3.5.1 Polymers3.5.2 Biofuels3.5.3 Enzymes3.5.4 Oils & Lubricants3.5.5 Other Renewables

4 Segmentation of Global Market by Technology4.1 Market Overview by Technology4.2 Genome Editing4.3 Synthetic Biology4.4 Genetic Engineering4.5 Marker-assisted Breeding4.6 Plant Breeding4.7 Germplasm4.8 Other Technologies

5 Segmentation of Global Market by Application5.1 Market Overview by Application5.2 Foliar Spray5.3 Seed Treatment5.4 Soil Treatment5.5 Other Applications

6 Segmentation of Global Market by Region6.1 Geographic Market Overview 2019-20306.2 North America Market 2019-2030 by Country6.2.1 Overview of North America Market6.2.2 U.S.6.2.3 Canada6.2.4 Mexico6.3 European Market 2019-2030 by Country6.3.1 Overview of European Market6.3.2 Germany6.3.3 U.K.6.3.4 France6.3.5 Spain6.3.6 Italy6.3.7 Russia6.3.8 Rest of European Market6.4 Asia-Pacific Market 2019-2030 by Country6.4.1 Overview of Asia-Pacific Market6.4.2 Japan6.4.3 China6.4.4 Australia6.4.5 India6.4.6 South Korea6.4.7 Rest of APAC Region6.5 South America Market 2019-2030 by Country6.5.1 Argentina6.5.2 Brazil6.5.3 Chile6.5.4 Rest of South America Market6.6 MEA Market 2019-2030 by Country6.6.1 UAE6.6.2 Saudi Arabia6.6.3 South Africa6.6.4 Other National Markets

7 Competitive Landscape7.1 Overview of Key Vendors7.2 New Product Launch, Partnership, Investment, and M&A7.3 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/hfydne

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Here is the original post:
Insights on the Agricultural Biotechnology Global Market to 2030 - Trend Forecasts and Growth Opportunities - PRNewswire

Dublin, Oct. 12, 2021 (GLOBE NEWSWIRE) -- The "Global Markets for Media, Sera and Reagents in Biotechnology" report has been added to ResearchAndMarkets.com's offering.

The current report offers a detailed picture of media, sera and reagents in biotechnology. This report highlights the current and future market potential for media, sera and reagents in biotechnology and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities and trends in the market.

This report also covers market projections through 2026 and key market players.

The global market for media, sera and reagents in biotechnology is estimated to grow from $5.0 billion in 2021 to $7.4 billion by 2026 at a compound annual growth rate (CAGR) of 7.9% of during the forecast period of 2021-2026.

North American market for media, sera and reagents in biotechnology is estimated to grow from $1.7 billion in 2021 to $2.3 billion by 2026 at a CAGR of 5.9% of during the forecast period of 2021-2026.

Asia-Pacific market for media, sera and reagents in biotechnology is estimated to grow from $1.2 billion in 2021 to $1.9 billion by 2026 at a CAGR of 9.5% of during the forecast period of 2021-2026.

The report details market shares of media, sera and reagents in cell culture. Market analysis in the media segment is divided into specialty media and classical media based on composition.

Based on formulation, the media are divided into powdered media and ready-to-use liquid media. Based on serum component, media are segmented into serum-free media and serum-requiring media. The market for sera is segmented based on the source of serum into fetal bovine serum and other sera which includes sera from animal sources such as goats, porcine, rabbits, etc.

The reagents market is segmented into reagents: biological response modifiers, cell dissociation reagents and others (amino acids, antibiotics, etc.). By geography, the market has been segmented into North America, Europe, the Asia-Pacific region, Middle East and Africa and South America. North America includes the U.S., Canada and Mexico, Europe includes Germany, the U.K., France, Italy, Spain and the Rest of Europe. The Asia-Pacific region includes China, India, Japan, Australia, New Zealand and the Rest of Asia-Pacific.

Story continues

Report Includes:

61 data tables and 44 additional tables

An updated review of current and future global markets for media, sera and reagents in the cell culture industry and its sub-segments

Analyses of the global market trends, with data from 2019-2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026

Discussion of major factors driving the growth of this market, industry structure, regulatory scenario, and penetration of technologies related to media, sera, and reagents in biotechnology

Estimation of the market size and market forecast for global media, sera, and reagents in biotechnology, and corresponding market share analysis by product type, end use, and region

Country specific data and market value analysis for the U.S., Canada, Mexico, Germany, UK, France, Italy, Spain, Japan, China, India, Australia and New Zealand, the Middle East and Africa

Highlights of emerging technology trends, opportunities and gaps estimating current and future demand for cell culture products; and impact analysis of COVID-19 on the progress of this market

A relevant patent analysis with significant allotments of patent issued for cell culture media, sera and reagents in biotechnology across each major category

Insight into the recent industry strategies, M&A deals of the major players operating within the global market; their key competitive landscape and company share analysis

Profile descriptions of the leading industry players, including Bio-Techne, Corning Inc., Fujifilm Holdings Corp., GE Healthcare, Merck KGaA and Thermo Fisher Scientific Inc.

Cell culture is the in vitro cultivation of cells in a controlled environment. Cell culture is gaining importance in biopharmaceutical industries with the growing demand for cell culture techniques in drug discovery and the production of biotherapeutics. Cell culture is used in academic research institutes to understand the physiology and biochemistry of cells.

Media, sera and reagents play an important role in the success of cell culture technology. The growing demand for novel therapeutics for the treatment of chronic disease and extensive research activities in regenerative medicine are anticipated to create high growth for media, sera and reagents during the forecast period.

The intent of this study is to provide readers with detailed information regarding cell culture, along with factors influencing market and key developments, with the goal of enabling decision-making regarding expansion and penetration in this market.

This report seeks to address the critically important topics of changing market dynamics, emerging players and technologies, strategies for accessing emerging markets and specific disease segments and geographies.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Industry Definitions

Historical Background of the Evolution of Cell Culture

Types of Cell Culture

Primary Culture

Secondary Culture

Morphology of Cells in Culture

Cell Culture Contamination and Quality Control

Cell Culture Contamination

Quality Controls in Cell Culture

Basic Components of Culture Media

Buffering Systems

Phenol Red

Inorganic Salts

Amino Acids

Carbohydrates

Proteins and Peptides

Fatty Acids and Lipids

Vitamins

Trace Elements

Media Supplements

Antibiotics

Serum

Cell Culture Applications

Chapter 4 Impact of COVID-19 Pandemic

Chapter 5 Market Dynamics

Market Drivers

Growing Demand

Technological Advancements

Expansion of Cell Cultures

R&D and Regenerative Medicines

Market Restraints

Ethical Issues and Regulatory Constraints

Lack of Skilled Technicians and Poor Infrastructure

Market Opportunities

Rising Demand for 3D Cell Cultures

Drug Discovery and Growing CRO

Chapter 6 Market Breakdown by Product Type

Global Market for Media, Sera and Reagents in Biotechnology, by Product Type

Reagents

Biological Response Modifiers (BRMs)

Cell Dissociation Reagents

Other Reagents

Market Size and Forecast

Media

Based on Serum

Based on Formulation

Based on Composition

Market Size and Forecast

Sera

Bovine Sera/Fetal Bovine Sera

Other Sera

Market Size and Forecast

Chapter 7 Market Breakdown by End Use

Chapter 8 Market Breakdown by Region

Chapter 9 Regulatory Scenarios

Introduction

Biological License Applications

Biological Administrative Actions

Recalls

Serum Regulatory Scenario

Chapter 10 Competitive Landscape

Chapter 11 Patent Analysis

Patents Granted by Year

Patents Granted by Type

Patents Granted by Company/Patent Holder

Patents Granted by Assignee's Country

Patents Granted by Assignee Type

Chapter 12 Company Profiles

Athena Environmental Sciences Inc.

Bio-Techne

Becton, Dickinson And Co. (Bd)

Go here to read the rest:
The Worldwide Media, Sera and Reagents in Biotechnology Industry is Expected to Reach $7.4 Billion by 2026 - Yahoo Finance

SAN CARLOS, Calif., October 11, 2021--(BUSINESS WIRE)--AcureX Therapeutics Corporation, a privately-held preclinical-stage biotechnology company focused on developing disease altering therapeutics for neurodegenerative diseases, today announced that it was selected to present at the Oppenheimer Biotechnology Emerging Science Summit on October 15th, 2021.

Presentation details:

Halting Neurodegeneration with Miro1 Directed TherapiesPresented by: William Shrader, Ph.D., Co-founder and CEO AcureX TherapeuticsDate and time: October 15th, 2021 at 1:30p.m. ET / 10:30a.m. PT

The Oppenheimer Biotechnology Emerging Science Summit will be held virtually and will feature Stanford Universitys SPARK program. Presentations will be given by experts in the fields of oncology, immunology, neurology, and gene therapy, as well as management from several publicly traded companies.

William Shrader, Ph.D. said, "We at AcureX are pleased to be recognized as a leader in an emerging field and we are delighted to share our novel drug discovery approach at this prestigious forum."

About AcureX Therapeutics

The mission of AcureX Therapeutics is to halt neurodegenerative diseases driven by impaired mitophagy, starting with Parkinsons Disease. AcureX expects to have one or more late-preclinical therapeutic candidates for Parkinsons in human trials within two years, followed by candidates for other neurodegenerative diseases. AcureXs novel approach and founding intellectual property are based on recent discoveries made by the companys inventor and co-founder, Xinnan Wang MD, Ph.D. AcureX has built a unique target and drug discovery platform to accelerate drug development and de-risk clinical trials with an exclusive license to the founding intellectual property. The AcureX team is led by veteran scientists with a proven track record in CNS drug development and serial life sciences entrepreneurs. For more information, please visit https://www.acurex.com.

Story continues

Oppenheimer Biotechnology Emerging Science Summit Registration

To express interest, please contact your Oppenheimer Institutional Salesperson or email Deena Sullivan at Deena.Sullivan@opco.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005102/en/

Contacts

Ashley Gonzalez, Ph.D.Info@acurex.com

Originally posted here:
AcureX Therapeutics to Present at Oppenheimer Biotechnology Emerging Science Summit - Yahoo Finance

Renowned industrialist and founder chairman of Praj Industries, Dr Pramod Chaudhari, who is popularly known as the Ethanol man, recently said that agricultural inputs form the base of biotechnology and these can be used to uplift the socio-economic status of farmers. Dr Chaudhari was speaking at an event held in his honour and hosted by United Western Business Forum at Hotel Sayaji in Wakad.

Dr Chaudhari was felicitated by Dr Anand Deshpande, the CMD of Persistent Systems, for being the first Indian recipient of the prestigious George Washington Carver Award, 2020.

Pune Mayor Murlidhar Mohol and PMRDA (Pune Metropolitan Region Development Authority) Commissioner Dr Suhas Diwase also attended the programme.

Dr Chaudhari said that biofuels are redefining transportation fuel mix and they also help combat climate change as they have low carbon content. The use of agricultural feedstock for production of biofuels provided an additional source of income to farmers, he added. Dr Chaudhari said that bio-based renewable chemicals and materials are the new frontier of bioeconomy.

Mohol said Dr Chaudharis achievement is a matter of pride for Puneites and added that People like Dr Chaudhari will inspire the youth of the city.

Dr Deshpande said an entrepreneur should always think about achieving the next level for his business, because any business can stagnate after reaching a certain level of success. He also suggested that a wide base of mentors was required to guide the entrepreneurs through difficult times.

The dean of alumni and corporate relations at IIT Bombay, Dr Suhas Joshi, said that the institute was in advanced stages of discussions with Dr Chaudhari for setting up a lifelong learning centre for IIT-B alumni. The institute has a strong base of over 65,000 alumni working across various segments and they have an urge to learn new skills from their alma mater, Joshi added.

Dr Diwase pointed out that biotechnology had the potential to make agriculture sustainable and economically viable. This will also help reduce urban influx and ease pressure on cities, he said. The current Covid-19 pandemic has shown the youth the importance of moving back to the fields rather than seeking opportunities in big cities, he said.

Read more from the original source:
Biotechnology can be used to improve condition of farmers, says Ethanol man - The Indian Express

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

NEW YORK, NY / ACCESSWIRE / October 15, 2021 / Sino United Worldwide Consolidated Ltd. (OTC PINK:SUIC) and Midas Touch Technology Ltd. have signed a strategic alliance partnership agreement with Taiwan Green Mountain Biotechnology Group to lead the countrywide marketing promotional activities and roadshows to kick off this quarter, aiming to establish 6,000 outlets in Taiwan and 30 other countries. SUIC, Midas are finalizing contracts with additional 5 partner distributors before the end of this year.

The partnership agreement was completed by the founder and Chairman of Green Mountain Biotechnology Group, Mr. Lin Jye and the CEO of Midas Touch, Mr. Joa Chen during a well-appointed signing ceremony hosted at the Taipei Regent Hotel on October 8, 2021 and attended by hundreds of merchants. The signing event had been widely covered by major media.

The Green Mountain Biotechnology Group is a leading beauty company in Taiwan specializing in manufacturing and marketing top quality skin care, makeup, fragrance and hair care products. The group Chairman, Mr. Lin Jye said, "This partnership with Midas Touch brings a positive energy that will benefit hundred thousands of business partners and generate tens of billions of dollars in business opportunities, while creating more than a million jobs in all parts of the world. Midas Touch has the mastery of operations and inventive approach that is unique and unparalleled in the market."

The Green Mountain Biotechnology group of companies has ten major business segments with a global scope covering more than 30 countries around the world. The holding group has captured the focus of major international media. It is one of the very few biotech companies in Taiwan that possesses cutting-edge technology research and development capabilities, global advanced production technology, and integrated brand marketing. The current product range covers medical and aesthetic skin care products, daily chemicals, nutritional supplements and smart living drinking water systems. Among the accolades it has gathered over the decades, its biotechnology company has received high recognition and won awards including the Taiwan Biotechnology Award, the Taiwan's No. 1 Brand Award, and the Taiwan Golden Quality Award, and the Global Quality Certification of Taiwan Ministry of Health. In addition to the Chinese market, the group's products are exported to more than 30 countries including the United States, Japan, South Korea, Malaysia, Singapore, the European Union, Thailand, Indonesia, Hong Kong, Macau, among others.

To learn more about Green Mountain Biotechnology group, please visit their website at:https://meihangjia.com/contact-us/

"SUIC-Midas is the first U.S. company that brings unique blockchain based solutions to Taiwan market for the digitization of real-world assets, unlocking their value in the process. We are very honored to have this opportunity to join the ranks of this pioneering "Supply Chain of Beauty" project and provide flexible funding strategies to businesses in the beauty industry and other industries in Taiwan and around the world. SUIC Midas not only offers one-of-a-kind solutions but also opportunities to grow businesses on a secure digital platform without losing the original characteristics of the physical assets. In January 2022, SUIC Midas will continue signing up more partners, while exclusive interviews with NASDAQ, Bloomberg, Fox Business and other major business news televisions have also been scheduled. This is a part of our global expansion plans to disrupt the traditional cash flow system and lead to the next generation of SUIC Midas supply chain finance ecosystem," explains Midas Touch media director, Henry Ho.

These five new partner distributors are expected to bring over 100,000 merchants which translates to $2 million royalty fees for the Midas Touch office in Taiwan. The New York and Malaysia offices will follow suit and launch the Starry Project before the end of the year, and will continue to launch in 40 countries in 2022/2023 replicating the Starry Project model and strategy.

About Midas Touch Technology Limited, United KingdomMidas Touch Technology Limited was established in the United Kingdom in 2010, is a duly registered company with a business license to operate. Midas Touch offers safeguards against fraud in the digital currency domain, e.g. counterfeit transfer of digital cash in wallets. Focus on digital asset management and provides enterprises with a decentralized finance (DeFi) and other comprehensive supply chain innovative financial services. Thereby, solve the capital turnover problems in both supply and demand sites. It has launched MT Flash Pay" Same Day Swipe-Funding, and MT CQ Pay" Emergency Loan with Double Revenues, MT Free Pay" Services - Delay Appropriation to Offset Transaction Cost and MT Unified Procurement" Combined Purchasing Powers Economies of Scale and several other financial solutions. To know more about Midas Touch, visit their website at http://www.midas-touch.io.

To learn more about Midas Touch product and services please review our information by clicking:https://drive.google.com/file/d/17GLXWv5T3d39Jrx2v0GvqKIBcSzxpOMy/view?usp=drivesdk

About Sino United Worldwide Consolidated Ltd., USAThe Sino United Worldwide Consolidated Ltd. provides research and development, venture financing for and investing in private enterprises and the public sector that develop products and services adopting core capabilities of the Internet of Things, cloud computing, mobile payment, Big Data, Blockchain, and Artificial Intelligence, to enhance and streamline existing processes, and establish new and exciting business models that will create revolutionary products and services. Shareholders of SUIC will be exposed to the diverse application of advanced services in various parts of the economy. Additionally, existing and potential customers can benefit from this company's diversified portfolio of technologies. As one of the pioneering publicly traded technology companies, SUIC will help build tech-enabled businesses of the future. To learn more, please visit http://www.sinounitedco.com.

Please also read the full company report on SUIC by Globe Small Cap Research LLC:https://drive.google.com/file/d/1_f2vaVOfJT5_idLn87lM1Q_lGxnY_tHW/view

Please also read the Updated Company PPT:https://drive.google.com/file/d/1jVOkxqxXFCRwrajwTQQ7xV7YIzn5wWF_/view?usp=sharing

Forward-Looking StatementCertain the information set forth herein contains "forward-looking information", including "future-oriented financial information"; and "financial outlook" under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of shares being offered hereunder; (iii) the expected development of the Company's business, projects, and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development, or otherwise under consideration; (vi) renewal of the Company's current agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained herein are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

ContactsSino United Worldwide Consolidated Ltd.New Release Department929-391-2550

SOURCE: Sino United Worldwide Consolidated Ltd.

View source version on accesswire.com: https://www.accesswire.com/668099/SUIC-Midas-Signed-Strategic-Partnership-Agreement-With-Taiwan-Biotech-Giant--Green-Mountain-Biotechnology-Group-To-Lead-The-Starry-Project-Countrywide-Roadshow-and-Global-Expansion-To-Open-6000-Outlets-in-30-Countries-SUIC-Midas-Is-Finalizing-The

The rest is here:
SUIC, Midas Signed Strategic Partnership Agreement With Taiwan Biotech Giant - Green Mountain Biotechnology Group To Lead The Starry Project...

PUNE, India, Oct. 15, 2021 /PRNewswire/ -- According to The Insight Partners study on "Contract Research Organization (CRO) Market to 2028 Global Analysis and Forecast by Type, End User, and Geography," the market is projected to reach US$ 88,835.19 million by 2028 from US$ 50,093.56 million in 2021; it is expected to grow at a CAGR of 8.5% during 20212028. The market growth is attributed to the surge in R&D expenditures and outsourcing activities, government initiatives to increase clinical trial participants, and rising number of clinical trials.

he Insight Partners Logo

North America would dominate the contract research organization (CRO) market in 2021. The market growth in the US is attributed to increasing research and development (R&D) expenditures. Various pharmaceutical companies are experiencing short profit margins due to patent expiry, which is compelling the spurring manufacturers to reduce their in-house R&D activities and outsource these activities to contract research organizations. Thus, the focus of biotechnology and pharmaceutical companies to lower the drug development costs propel the market in the US.

Get Exclusive Sample Pages of Contract Research Organization (CRO) Market at https://www.theinsightpartners.com/sample/TIPBT00002008/

Based on type, the contract research organization (CRO) market is segmented into early phase services, clinical research services, laboratory services, and post-approval services. The early phase services segment is further bifurcated into drug discovery services and preclinical services. The clinical research services segment is the largest shareholder in the market and is expected to register the highest CAGR during the forecast period. By end user, the contract research organization (CRO) market is segmented into pharmaceutical and biotechnology companies, and medical devices companies. The pharmaceutical and biotechnology companies segment holds a larger share of the market, and it is anticipated to register a higher CAGR in the market during the forecast period.

Story continues

Increasing R&D Expenditures and Outsourcing Activities Fuel Contract Research Organization (CRO) Market Growth

R&D is an essential and crucial part of any company's business. Pharmaceutical and biotechnology companies focus on the R&D to come up with new molecules or active ingredients with the greatest medical and commercial potential for various therapeutic applications. Companies invest majorly on R&D for delivering high-quality and innovative products to the markets they serve. Research and development expenditures entail spending on the discovering, testing, and developing new products; making upfront payments and milestones; improving existing products; and demonstrating product efficacy and regulatory compliance prior to launch. According to the International Federation of Pharmaceutical Manufacturers & Associations, in 2019, the R&D expenditures by the pharmaceuticals and biotechnology industry grew by ~20% than those in 2015.

With the second wave of COVID-19, there has been an increasing number of cases in Latin American countries. With the high focus on treating the disease, governments in this region are encouraging clinical programs to fight against the novel coronavirus. Moreover, the majority of manufacturing companies have channelized their efforts toward developing therapeutics against this disease. Thus, the pandemic has had a slightly negative effect on other healthcare markets, such as contract research organization market.

Download the Latest COVID-19 Analysis on Contract Research Organization (CRO) Market Growth Research Report at https://www.theinsightpartners.com/covid-analysis-sample/TIPBT00002008/

Contract Research Organization (CRO) Market: Segmental Overview

Based on end user, the pharmaceutical and biotechnology companies' segment is anticipated to register a higher CAGR in the contract research organization (CRO) market during the forecast period.

Contract Research Organization (CRO) Market: Competitive Landscape and Key Developments

IQVIA Inc; Parexel International Corporation; Charles River Laboratories, Inc.; ACM Global Laboratories; Merck KGaA (Bio Reliance Corporation); Celerion; Clinitude; Laboratory Corporation of America Holdings (Covance Inc.); Novotech; and Icon PLC are among the key companies operating in the contract research organization (CRO) market. Leading players focus on launch of new products, expansion and diversification of market presence, and acquisition of new customer base for tapping the prevailing business opportunities.

In June 2021, Charles River Laboratories completed the acquisition of Vigene Biosciences for US$ 292.5 million in cash. The acquisition of Vigene Biosciences' extensive gene therapy capabilities further enhances Charles River's position as a premier scientific partner for cell and gene therapies.

Order a Copy of Contract Research Organization (CRO) Market Shares, Strategies and Forecasts 2021-2028 Research Report at https://www.theinsightpartners.com/buy/TIPBT00002008/

In April 2021, IQVIA acquired Q2 Solutions, a clinical laboratory services organization of Quest Diagnostics.

In November 2020, WuXi Apptec expanded its Cell & Gene Therapy Platforms with capabilities to provide high-quality and cost-effective supplies of R&D and GMP plasmids.

Browse Related Reports:

About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us: If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi E-mail: sales@theinsightpartners.com Phone: +1-646-491-9876More Research: https://www.openpr.com/news/archive/139407/The-Insight-Partners.html

Cision

View original content:https://www.prnewswire.com/news-releases/contract-research-organization-cro-market-size-88-83-billion-by-2028-growth-forecast-at-8-5-cagr-during-2021-to-2028-covid-impact-and-global-analysis-by-the-insight-partners-301400770.html

SOURCE The Insight Partners

Originally posted here:
Contract Research Organization (CRO) Market Size ($88.83 Billion by 2028) Growth Forecast at 8.5% CAGR During 2021 to 2028 COVID Impact and Global...